It is understandable to want a number and a date. Human biology is not that uniform. Good obesity care follows the individual rather than promising the same result to everyone.

Evidence-based and personal

A study average is a reference point—not a limit.

Clinical trials report group averages. Within every trial, some participants lose more, some lose less, and some stop treatment because of side effects, health changes, access, or personal preference. Results may also vary with the treatment used, other medical conditions and medications, tolerability, consistency, and the intensity of support provided.1,2,3

No study average can tell one person exactly how much weight may be lost or how long the full journey may take. Someone beginning with substantially more weight to lose should not interpret a trial percentage as a ceiling. Progress may continue beyond an early benchmark or the follow-up period reported in a study.

Population data can frame expectations, but it cannot define one person's target or pace. Starting health, biology, treatment response, tolerability, consistency, interruptions, access, and life circumstances all influence what may be possible. Every patient deserves a plan that responds to their progress, health, goals, and circumstances rather than forcing the same path on everyone.

The useful question is not “Can everyone reach the same number by the same date?”

Is this plan safe, effective, sustainable, and still moving me toward my goals?

Want to understand what different percentages may mean for health? Explore the weight loss response guide.

Progress has a rhythm

Dose adjustment takes time—and care continues throughout.

Many weight-loss medications used in this clinic are started at a low dose and adjusted gradually over several months. Some patients respond well at a lower dose; others benefit from additional adjustments. That individualized process can take four to six months to settle into a useful treatment rhythm.2,3 Dr. Olson will assess your progress, tolerability, and safety multiple times during that window and tailor the plan as needed.4,5

Early weeks to first 3 monthsBegin + adjust

Review response and safety while the dose is gradually adjusted when appropriate.

Months 4–6Find a useful rhythm

Review the developing response in context and continue individualized adjustments only when needed.

Longer termContinue + personalize

Build on progress, adapt when needed, and keep care connected through every phase—including after reaching goal.

A slower start does not always predict the longer-term result.

In a post hoc analysis of SURMOUNT-1, participants taking tirzepatide who had lost less than 5% at week 12 still averaged 11.0% weight loss by week 72; 90% ultimately reached at least 5% weight loss. This finding describes one analyzed trial group—not an individual forecast or a reason to continue a treatment that is unsafe, poorly tolerated, or no longer appropriate. It does support giving a medically supervised plan enough time to reveal its pattern before judging it by an early snapshot alone.6

Four to six months is not a deadline or a waiting period. Dr. Olson will review progress, tolerability, and safety multiple times during that window. Some people respond early; others need more time or different medically guided adjustments. Health changes, interruptions, and patient priorities also shape what comes next.

Safety concerns should never wait for a scheduled checkpoint. New or severe symptoms, pregnancy, a planned procedure, a major illness, or an important change in other medications should be reported promptly to the appropriate clinician.

What research averages show

Headline results are measured over months—not a few weeks.

Different approaches work on different timelines, and the amount of support inside a study matters. Intensive lifestyle trials often include far more contact than routine medical care. Medication trials study selected populations using defined doses and protocols.

STEP 168 weeks

Average 14.9% loss with semaglutide plus lifestyle intervention among adults without diabetes.2

SURMOUNT-172 weeks

Average 15.0% to 20.9% loss across studied tirzepatide doses plus lifestyle intervention among adults without diabetes.3

Group averages—not individual forecasts or ceilings

These figures describe particular trial populations, doses, protocols, and follow-up periods. They should not predict one person's outcome, and separate trials are not head-to-head comparisons. They do reinforce an important timing point: these headline results were measured after roughly 16 months.2,3

A study average provides context—not a ceiling. Some participants lose less, some are near the average, and some lose substantially more over time. For a person beginning at a much higher weight, a medically appropriate journey may continue well beyond the percentage highlighted in a trial. The individual trend, health, tolerability, goals, and circumstances guide what should happen next.

In structured lifestyle research, the NIH Diabetes Prevention Program used at least 16 individual meetings in its first 24 weeks, followed by continued contact. Look AHEAD used frequent individual and group counseling, especially in its first year. Those were high-contact research programs—not promises for routine nutrition advice or a standard office visit.7,8

A normal part of long-term care

A plateau—or a period of regain—is information, not a verdict.

Weight does not usually move in a straight line. Hydration, sodium, bowel patterns, menstrual-cycle changes, illness, travel, and measurement conditions can temporarily move the scale. One flat week is not a true plateau.1

Illustrative long-term weight trend with plateaus and temporary regainAn illustrative weight trend moves generally lower over time, with periods of slower progress, two modest regains, reconnection where the trend turns again, and a later plateau before progress continues. Possible interruptions include vacation, grief or caregiving, illness or surgery, and financial or competing life priorities.HigherLowerTime123456
  1. 1Vacation
  2. 2Reconnect when ready
  3. 3Grief or caregiving
  4. 4Surgery or illness
  5. 5Finances or life priorities
  6. 6Reconnect when ready
Illustrative pattern—not a forecast. Real progress may include loss, maintenance, plateaus, and periods of regain.

Life continues during treatment. Grief, caregiving, a demanding season at work, illness, surgery and recovery, travel, financial or medication-access difficulties, or other personal priorities can interrupt a plan and contribute to a plateau or regain. These changes are not failure. Give yourself some grace.

Regular follow-up supports the plan while care is moving forward. If life interrupts care or progress, I will meet you where you are, help identify what is workable and safe now, and reconnect the plan when your circumstances allow. A pause or period of regain does not erase the progress you have already made.

When a trend has been flat long enough to be clinically meaningful, the next step is to review measurement quality, treatment use, nutrition and movement patterns, sleep, stress, side effects, other medications, new diagnoses, access, and goals. Sometimes the right response is to continue and observe. Sometimes it is to adjust, switch, investigate, or focus intentionally on maintenance.

Maintenance is not “nothing happening.” Holding onto a clinically meaningful improvement is an active treatment outcome.

Reaching goal is not the end of care.

Your health is a lifelong journey—not a race with a finish line. Ongoing care helps protect progress and allows the plan to evolve as your health, needs, and life circumstances change.

Clinical reassessment

Reassessment is how the plan stays useful and safe.

  1. 01

    The expected trend is not developing

    A fair assessment depends on the treatment being used, the individual response and tolerability, consistency, and any interruptions—not simply the date care began.

  2. 02

    Side effects or safety concerns need attention

    Your well-being matters more than any number on the scale. New symptoms or other clinically important concerns are reasons to check in and adjust the plan together.

  3. 03

    Health circumstances change

    New medicines, illness, surgery, pregnancy plans, or changes in another condition may alter what is appropriate.

  4. 04

    The plan no longer fits your current circumstances

    If cost, access, scheduling, administration, or day-to-day demands make the plan harder to follow, please bring that up. Those challenges are real, and we can discuss what may be more workable.

  5. 05

    Goals or preferences change

    The best plan must remain medically sound and workable for the person living with it.

Reassessment may lead to continuing, adjusting the pace, changing treatment, addressing a barrier, coordinating with another clinician, or planning the next phase of ongoing care. More treatment is not always better; the goal is the right treatment for the person's current health and circumstances.1,4

Prepare for your visit

Questions worth bringing to your physician

  • Which outcomes are most important for my health—not only my weight?
  • When will we first reassess whether this plan is working?
  • How will we account for medication adjustments or a treatment interruption?
  • Which symptoms or changes should I report before my next visit?
  • Which measurements should my PCP or another specialist continue to manage?
  • If my trend slows, how will we decide whether to maintain, investigate, or adjust?
The bottom line

Many medication plans involve gradual dosage adjustments over several months, and finding a useful rhythm can take four to six months. Care and safety monitoring continue throughout. Patience, consistency, and medical supervision give the plan time to work while helping your physician personalize what should continue or change.

Evidence and further reading

Sources behind this article

  1. [1] JAMA review: obesity management in adults
  2. [2] STEP 1 randomized trial
  3. [3] SURMOUNT-1 randomized trial
  4. [4] AACE 2025 adult obesity-care consensus
  5. [5] Endocrine Society obesity-pharmacotherapy guideline
  6. [6] SURMOUNT-1 post hoc analysis: outcomes among early and late responders
  7. [7] NIDDK: Diabetes Prevention Program
  8. [8] NIDDK: Look AHEAD study

This article provides general education and is not individualized medical advice, diagnosis, or treatment. Individual results may vary and are not guaranteed. Contact the appropriate clinician for treatment changes and seek urgent care for severe symptoms.